Tekturna

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2014
02420072014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Health care providers managing hypertension (HTN) have a large selection of pharmacologic agents to choose from, including… (More)
Is this relevant?
2012
2012
A new approach to the synthesis of Tekturna, a recently marketed drug for hypertension, takes advantage of a modified protocol of… (More)
Is this relevant?
Review
2010
Review
2010
The role of renin-angiotensin-aldosterone system (RAAS) in regulating the volume and composition of extracellular fluid, blood… (More)
Is this relevant?
Review
2009
Review
2009
The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus… (More)
Is this relevant?
Review
2008
Review
2008
Aliskiren, a renin inhibitor, is the first in a new class of drugs interfering with the renin angiotensin system. Aliskiren was… (More)
Is this relevant?
Review
2008
Review
2008
Aliskiren (Tekturna or Rasilez) is an orally active renin inhibitor approved for the treatment of hypertension.1 As with… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2007
Review
2007
At Ciba-Geigy (now Novartis), the clinical development of the CGP38560 renin inhibitor was halted due to insufficient… (More)
Is this relevant?
Review
2007
Review
2007
Aliskiren (CGP-60536 or SPP100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be… (More)
Is this relevant?
Review
2007
Review
2007
  • The Medical letter on drugs and therapeutics
  • 2007
 
Is this relevant?
2007
2007
Aliskiren (Tekturna; Speedel/Novartis) is the first in a new class of drugs that inhibit the protease renin, which has a key role… (More)
  • figure 1
Is this relevant?